FLUCONAZOLE ( DrugBank: Fluconazole )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	4
225	Congenital nephrogenic diabetes insipidus	1

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03476317 (ClinicalTrials.gov)	July 12, 2018	8/1/2018	Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	An Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Crohn Disease	Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Fluconazole	Children's Hospital of Philadelphia	University of Pennsylvania;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	6 Years	N/A	All	10	Phase 2	United States
2	NCT02765256 (ClinicalTrials.gov)	August 2016	2/5/2016	Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Crohn's Disease	Drug: Fluconazole;Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Promethazine;Drug: Fluconazole placebo	University of Pennsylvania	Children's Hospital of Philadelphia;Crohn's and Colitis Foundation	Completed	18 Years	75 Years	All	8	Phase 2	United States
3	EUCTR2008-003167-39-BE (EUCTR)	17/09/2008	28/08/2008	Effet du fluconazole sur le taux d'anticorps anti-Saccharomyces cerevisiae (ASCSA) après résection chirurgicale pour maladie de Crohn.	Effet du fluconazole sur le taux d'anticorps anti-Saccharomyces cerevisiae (ASCSA) après résection chirurgicale pour maladie de Crohn.	Crohn' disease MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease	Trade Name: diflucan INN or Proposed INN: FLUCONAZOLE	Cliniques Universitaires Saint Luc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60		Belgium
4	NCT02997059 (ClinicalTrials.gov)	July 2008	14/12/2016	Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.	Effect of Fluconazole on the Levels of Anti-Saccharomyces Cerevisiae Antibodies (ASCA) After Surgical Resection for Crohn's Disease. Multicenter, Randomized, and Controlled in Two Parallel Groups Versus Placebo	Crohn's Disease Aggravated	Drug: Fluconazole;Other: Placebo	University Hospital, Lille	Ministry of Health, France	Terminated	18 Years	N/A	Both	35	Phase 2	France

225. Congenital nephrogenic diabetes insipidus

---

Clinical trials : 15 /  Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-002204-38-DK (EUCTR)	24/11/2020	07/05/2020	Treatment of the genetic disease nephrogenic diabetes insipidus with the antifungal drug Fluconazole	Treatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication	Nephrogenic diabetes insipidus MedDRA version: 21.0;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	INN or Proposed INN: Fluconazole Other descriptive name: FLUCONAZOLE	Claus Bistrup	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	10	Phase 2	Denmark

Back to top